News
Whether stemming from early childhood adversity, combat exposure, or interpersonal abuse, trauma leaves long-term imprints on ...
Improving efficiencies and uncomplicating processes are critical to the future success of NHS Trusts across the country. The ...
Taiho Pharmaceutical has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy ...
Boehringer Ingelheim has raised hopes of a more patient-friendly option with the start of phase 2 testing of BI 1815368, ...
The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands ...
A new formulation of Novartis' antimalarial Coartem has become the first medicine to be approved for use in very young ...
South Korean electronics giant Samsung has continued a push into the health category with an agreement to buy Xealth, a ...
Medistry LLC is the internet registry operator of the .med top level domain (TLD). Currently in a period of pre-registration ...
After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS ...
The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?
Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibi ...
BIO Boston: 2025 is shaping up to be a year of challenge – but also opportunity – say biotech bosses
So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results